Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors
- 1 April 2014
- journal article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 28 (6) , 531-539
Abstract
To demonstrate the safety of outpatient 7.8 GBq 177Lu-DOTA-tyr3-octreotate radiopeptide therapy of neuroendocrine tumors by measurement of radiation exposures of hospital personnel, carers and members of the public. Seventy-six patients with progressive, metastatic neuroendocrine tumors each received four cycles of prescribed activity of 7.8 GBq 177Lu-octreotate at 8-week intervals, as an outpatient procedure. Cohorts comprising four patients were treated in one room, each patient remaining in hospital until radiation exposure from them was below the release limit of 25 μSv h−1 at 1 m. On occasion, a single patient was treated in a single room. Radiation exposures of hospital staff and patient carers were monitored by personal dosimeter, and nearby areas monitored with a survey meter. Mean whole-body radiation exposures per therapy day ranged from 8 μSv (physicist) to 33 μSv (nurse), with exposures to personnel, carers and members of the public well within the limits recommended by the International Commission on Radiological Protection. Patients excreted a mean of 46 % of the total administered activity of 177Lu-octreotate within 4 h of therapy. Lutetium-177-octreotate radiopeptide therapy of neuroendocrine tumors can be safely performed as an outpatient treatment.Keywords
This publication has 18 references indexed in Scilit:
- Phase I-II Study of Radiopeptide 177 Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine TumorsCancer Biotherapy and Radiopharmaceuticals, 2012
- Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine NeoplasmsSeminars in Nuclear Medicine, 2012
- Automated Module Radiolabeling of Peptides and Antibodies with Gallium-68, Lutetium-177 and Iodine-131Cancer Biotherapy and Radiopharmaceuticals, 2012
- Outpatient therapeutic nuclear oncologyAnnals of Nuclear Medicine, 2012
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnalogsNeuroendocrinology, 2009
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008